Literature DB >> 21527148

The treatment of Dupuytren disease.

Shaunak S Desai1, Vincent R Hentz.   

Abstract

The treatment of progressive Dupuytren contractures has historically been and continues to be largely surgical. Although a number of surgical interventions do exist, limited palmar fasciectomy continues to be the most common and widely accepted treatment option. Until recently, nonsurgical options were limited and clinically ineffective. However, the commercial availability and recent approval of collagenase clostridium histolyticum now provides practitioners with a nonsurgical approach to this disease. This article presents a comprehensive review of the surgical and nonsurgical treatments of Dupuytren disease, with a focus on collagenase.
Copyright © 2011 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21527148     DOI: 10.1016/j.jhsa.2011.03.002

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  30 in total

1.  Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren's disease.

Authors:  R Arora; P Kaiser; T-J Kastenberger; G Schmiedle; S Erhart; M Gabl
Journal:  Oper Orthop Traumatol       Date:  2015-12-18       Impact factor: 1.154

Review 2.  [Percutaneous needle aponeurotomy for Dupuytren's contracture].

Authors:  J Oppermann; F Unglaub; L P Müller; S Löw; P Hahn; C K Spies
Journal:  Orthopade       Date:  2017-04       Impact factor: 1.087

3.  Factors influencing recurrence and progression of Dupuytren's disease treated by Collagenase Clostridium histolitycum.

Authors:  Clarisa Simón-Pérez; Julian Alía-Ortega; Belen García-Medrano; Jose Ignacio Rodríguez-Mateos; Maria Brotat-Rodríguez; Hector Aguado-Hernandez; Miguel Angel Martín-Ferrero
Journal:  Int Orthop       Date:  2017-11-23       Impact factor: 3.075

4.  SNPs previously associated with Dupuytren's disease replicated in a North American cohort.

Authors:  Eric R Anderson; Zhan Ye; Michael D Caldwell; James K Burmester
Journal:  Clin Med Res       Date:  2014-02-26

Review 5.  Dupuytren's disease: current state of the art.

Authors:  Mark Henry
Journal:  Hand (N Y)       Date:  2014-03

Review 6.  Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects.

Authors:  María Alejandra Egui Rojo; Ignacio Moncada Iribarren; Joaquín Carballido Rodriguez; Juan Ignacio Martinez-Salamanca
Journal:  Ther Adv Urol       Date:  2014-10

7.  [Treatment of Dupuytren's disease with collagenase Clostridium histolyticum].

Authors:  M Keller; R Arora; G Schmiedle; T Kastenberger
Journal:  Orthopade       Date:  2017-04       Impact factor: 1.087

8.  Proposal for Treatment of Severe Dupuytren Disease in 2 Steps: Progressive Distraction With External Fixator and Collagenase - A Preliminary Case Series.

Authors:  Massimo Corain; Filippo Zanotti; Roberta Sartore; Paolo Pozza
Journal:  Hand (N Y)       Date:  2019-02-22

9.  Systematic Review Comparing Cost Analyses of Fasciectomy, Needle Aponeurotomy, and Collagenase Injection for Treatment of Dupuytren's Contracture: Une analyse de coûts systématique comparant la fasciectomie, l'aponévrotomie percutanée à l'aiguille et l'injection de collagénase pou traiter la maladie de Dupuytren.

Authors:  Alanna Victoria Fitzpatrick; Syena Moltaji; Maleka Ramji; Stuart Martin
Journal:  Plast Surg (Oakv)       Date:  2020-10-16       Impact factor: 0.947

10.  Psychometric properties of health-related quality of life instruments in patients undergoing palmar fasciectomy for dupuytren's disease: a prospective study.

Authors:  Achilleas Thoma; Manraj Nirmal Kaur; Teegan Aili Ignacy; Carolyn Levis; Stuart Martin; Eric Duku; Ted Haines
Journal:  Hand (N Y)       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.